Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
OXGN's Cash to Debt is ranked higher than
85% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. OXGN: No Debt )
OXGN' s 10-Year Cash to Debt Range
Min: 23.3   Max: No Debt
Current: No Debt

Interest Coverage No Debt
OXGN's Interest Coverage is ranked higher than
75% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OXGN: No Debt )
OXGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 3.20
M-Score: -3.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -12738.95
OXGN's Operating margin (%) is ranked lower than
51% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. OXGN: -12738.95 )
OXGN' s 10-Year Operating margin (%) Range
Min: -1304800   Max: -35.75
Current: -12738.95

-1304800
-35.75
Net-margin (%) -12743.16
OXGN's Net-margin (%) is ranked lower than
51% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. OXGN: -12743.16 )
OXGN' s 10-Year Net-margin (%) Range
Min: -1190900   Max: -41.98
Current: -12743.16

-1190900
-41.98
ROE (%) -58.16
OXGN's ROE (%) is ranked higher than
65% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. OXGN: -58.16 )
OXGN' s 10-Year ROE (%) Range
Min: -8738.97   Max: -20.07
Current: -58.16

-8738.97
-20.07
ROA (%) -54.11
OXGN's ROA (%) is ranked higher than
63% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. OXGN: -54.11 )
OXGN' s 10-Year ROA (%) Range
Min: -224.41   Max: -15.51
Current: -54.11

-224.41
-15.51
ROC (Joel Greenblatt) (%) -46190.84
OXGN's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. OXGN: -46190.84 )
OXGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -34348.94   Max: -250.74
Current: -46190.84

-34348.94
-250.74
EBITDA Growth (%) -62.50
OXGN's EBITDA Growth (%) is ranked higher than
51% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. OXGN: -62.50 )
OXGN' s 10-Year EBITDA Growth (%) Range
Min: -66.2   Max: 23.9
Current: -62.5

-66.2
23.9
EPS Growth (%) -59.70
OXGN's EPS Growth (%) is ranked higher than
52% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. OXGN: -59.70 )
OXGN' s 10-Year EPS Growth (%) Range
Min: -67.4   Max: 21.5
Current: -59.7

-67.4
21.5
» OXGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

OXGN Guru Trades in Q4 2012

John Keeley Sold Out
» More
Q2 2013

OXGN Guru Trades in Q2 2013

Jim Simons 17,585 sh (New)
» More
Q3 2013

OXGN Guru Trades in Q3 2013

Jim Simons 39,960 sh (+127.24%)
» More
Q4 2013

OXGN Guru Trades in Q4 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with OXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Keeley 2012-12-31 Sold Out $0.34 - $5.29 $ 1.87267%0
John Keeley 2012-06-30 New Buy$0.62 - $1.1 $ 1.87106%28000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.20
OXGN's P/B is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. OXGN: 1.20 )
OXGN' s 10-Year P/B Range
Min: 0.24   Max: 12.17
Current: 1.2

0.24
12.17
EV-to-EBIT -0.45
OXGN's EV-to-EBIT is ranked higher than
50% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OXGN: -0.45 )
OXGN' s 10-Year EV-to-EBIT Range
Min: -15.4   Max: 0.6
Current: -0.45

-15.4
0.6
Current Ratio 19.81
OXGN's Current Ratio is ranked higher than
95% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OXGN: 19.81 )
OXGN' s 10-Year Current Ratio Range
Min: 0.81   Max: 58.71
Current: 19.81

0.81
58.71
Quick Ratio 19.81
OXGN's Quick Ratio is ranked higher than
95% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. OXGN: 19.81 )
OXGN' s 10-Year Quick Ratio Range
Min: 0.81   Max: 58.71
Current: 19.81

0.81
58.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.20
OXGN's Price/Net Cash is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. OXGN: 1.20 )
OXGN' s 10-Year Price/Net Cash Range
Min: 0.88   Max: 347.97
Current: 1.2

0.88
347.97
Price/Net Current Asset Value 1.20
OXGN's Price/Net Current Asset Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. OXGN: 1.20 )
OXGN' s 10-Year Price/Net Current Asset Value Range
Min: 0.88   Max: 347.97
Current: 1.2

0.88
347.97
Price/Tangible Book 1.20
OXGN's Price/Tangible Book is ranked higher than
98% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. OXGN: 1.20 )
OXGN' s 10-Year Price/Tangible Book Range
Min: 0.83   Max: 18.18
Current: 1.2

0.83
18.18
Earnings Yield (Greenblatt) -219.80
OXGN's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. OXGN: -219.80 )
OXGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -219.8   Max: 13745.9
Current: -219.8

-219.8
13745.9
Forward Rate of Return (Yacktman) -354.55
OXGN's Forward Rate of Return (Yacktman) is ranked lower than
51% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. OXGN: -354.55 )
OXGN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3726.8   Max: -3.6
Current: -354.55

-3726.8
-3.6

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:OXGP.Germany
OxiGene, Inc. was incorporated in 1988 in the state of New York and reincorporated in 1992 in the state of Delaware. The Company is a clinical-stage biopharmaceutical company that develops therapeutics to treat cancer and eye diseases. The Company primarily focuses on the development of vascular disrupting agents that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, and also are associated with visual impairment in a various ophthalmological diseases and conditions. Its principal product candidate includes ZYBRESTAT, a reversible tubulin binding agent for the treatment of anaplastic thyroid cancer, medullary thyroid cancer, Stage IV papillary thyroid cancer, Stage IV follicular thyroid cancer, carcinoid syndrome, and ovarian cancer. The company is also developing ZYBRESTAT for ophthalmological diseases and conditions that are characterized by abnormal blood vessel growth within the eye that result in loss of vision. In addition, it is developing OXi4503 for the treatment for certain solid tumor types and for the treatment of myeloid leukemias.
» More Articles for NAS:OXGN

Headlines

Articles On GuruFocus.com
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
OXiGENE Inc. Reports Operating Results (10-Q) May 14 2010 
OXiGENE Inc. Reports Operating Results (10-Q) Nov 10 2009 
OXiGENE Inc. Reports Operating Results (10-Q) Aug 13 2009 
OXiGENE Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Nov 26 2014
OXIGENE INC Financials Nov 21 2014
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of... Nov 20 2014
OXiGENE Announces Preclinical Poster Presentation on OXi4503 at Upcoming American Society of... Nov 20 2014
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other... Nov 17 2014
OXiGENE Announces Issuance of European Patent for OXi4503 in Acute Myeloid Leukemia and other... Nov 17 2014
10-Q for Oxigene, Inc. Nov 15 2014
OXIGENE INC Files SEC form 10-Q, Quarterly Report Nov 13 2014
OXIGENE INC Earnings Call scheduled for 4:30 pm ET today Nov 12 2014
OXiGENE Reports Third Quarter 2014 Financial Results Nov 12 2014
OXIGENE INC Files SEC form 8-K, Results of Operations and Financial Condition Nov 12 2014
OXiGENE Reports Third Quarter 2014 Financial Results Nov 12 2014
Q3 2014 OXiGENE Inc Earnings Release - After Market Close Nov 12 2014
Oxigene Faces Challenges for Ovarian Cancer Drug Even With Encouraging Data Nov 12 2014
OXIGENE INC Files SEC form 8-K, Other Events Nov 10 2014
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to... Nov 10 2014
OXiGENE Announces Presentation of Phase 2 Data Confirming That Addition of Fosbretabulin to... Nov 10 2014
Coverage initiated on OXiGENE by MLV & Co Nov 07 2014
OXiGENE Announces Third Quarter 2014 Earnings Conference Call and Webcast Oct 22 2014
OXIGENE INC Files SEC form 8-K, Other Events Oct 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK